Vertex Pharma to Submit Kidney-Disease Drug Application to FDA by Year-End

As part of the FDA's rolling review of the biologics license application, Vertex expects to submit the first module to the regulator for potential accelerated approval before the end of 2025, and said ...
Zacks Investment Research on MSN

Vertex Pharmaceuticals (VRTX) Outpaces Stock Market Gains: What You Should Know

Vertex Pharmaceuticals (VRTX) ended the recent trading session at $416.81, demonstrating a +2.01% change from the preceding day's closing price. The stock's performance was ahead of the S&P 500's ...